Omalizumab: NICE to USE you, to LOSE you NICE.

@article{Bush2013OmalizumabNT,
  title={Omalizumab: NICE to USE you, to LOSE you NICE.},
  author={Andy Bush and Ian D. Pavord},
  journal={Thorax},
  year={2013},
  volume={68 1},
  pages={
          7-8
        }
}
National Institute for Health and Clinical Excellence (NICE) has just published draft recommendations for the use of omalizumab. These are as follows: 1. Omalizumab is not recommended within its marketing authorisation for treating severe persistent allergic asthma 2. People currently taking omalizumab should be able to continue treatment until they and their clinician consider it appropriate to stop. For children and adolescents, this decision should be made jointly by the clinician, the… CONTINUE READING
12
Twitter Mentions

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

Neue Strategien in der Asthmatherapie

VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Novel strategies for the treatment of asthma

VIEW 1 EXCERPT
CITES BACKGROUND

Severe asthma: definition, diagnosis and treatment.

VIEW 2 EXCERPTS
CITES BACKGROUND

Newer Treatments in the Management of Pediatric Asthma

VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 13 REFERENCES

A proofofconcept randomizedcontrolled trial of omalizumab in patients with severe dif fi cult to control nonatopic asthma ( abstract )

  • ID Pavord, A Bush
  • Eur Respir J
  • 2012

Diagnosis and de fi nition of severe refractory asthma : an international consensus statement from the Innovative Medicine Initiative ( IMI )

  • ID Pavord, S Korn, P Howarth
  • Thorax
  • 2011

Non - adherence in dif fi cult asthma : time to take it seriously

  • A Bush, W Lenney, D Spencer
  • Thorax
  • 2011